Eli Lilly has brought patent litigations against several generic drug manufacturers who have challenged a patent protecting its blockbuster anti-cancer drug Alimta®. In one of those cases, Williams & Connolly served as lead counsel for Eli Lilly before the U.S. District Court for the Southern District of Indiana in a Hatch-Waxman patent infringement action against Dr. Reddy Laboratories, which was tried in February 2018. The focus of the trial was on whether Dr. Reddy’s pemetrexed ditromethamine product infringes Eli Lilly’s patent which covers a method of administration of Alimta® with folic acid and vitamin B12. On June 22, 2018, the Court ruled in favor of Eli Lilly, finding the use of Dr. Reddy’s product would infringe Eli Lilly’s patent and that Dr. Reddy’s was liable for indirect infringement.
The team representing Eli Lilly includes Adam Perlman, Dov Grossman, David Krinsky, Galina Fomenkova, Alec Swafford, and Andrew Lemens.
Please click here to read the full opinion.